Selection of S18326 as a new potent and selective boronic acid direct thrombin inhibitor

Thrombosis and Haemostasis

Volumn 78, Issue 4, 1997, Pages 1221-1227

  Rupin, A ^b   Mennecier, P ^b   Lila, C ^a   De Nanteuil, G ^a   Verbeuren, T J ^b  

^a Division of Medicinal Chemistry   (France)

^b INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYL DEXTRO PHENYLALANYLPROLYLBOROARGININE; ACTIVATED PROTEIN C; BORONIC ACID DERIVATIVE; COMPLEMENT FACTOR I; FIBRINOGEN; KALLIKREIN; PLASMIN; PROLINE; S 18229; S 18326; S 18563; S 18989; SERINE PROTEINASE; THROMBIN; THROMBIN INHIBITOR; UNCLASSIFIED DRUG; UROKINASE;

ARTICLE; BLOOD CLOTTING; CONTROLLED STUDY; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; ENZYME ASSAY; FIBRINOLYSIS; HUMAN; PLASMA; PRIORITY JOURNAL;

EID: 0030679694     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1657718     Document Type: Article

References (16)

1. Kettner C, Mersinger L, Knabb R. The selective inhibition of thrombin by peptides of boroarginine. J Biol Chem 1990; 265: 18289-97.
2. Hussain MA, Knabb R, Aungst BJ, Kettner C. Anticoagulant activity of a peptide boronic acid thrombin inhibitor by various routes of administration in rats. Peptides 1991; 12: 1153-4.
3. Tapparelli C, Metternich R, Ehrhardt C, Zurini M, Cleason G, Scully MF, Stone SR. In vitro and in vivo characterization of a neutral boron-containing thrombin inhibitor. J Biol Chem 1993; 268: 4734-41.
4. De Nanteuil G, Gloanec P, Lila C, Portevin B, Boudon A, Rupin A, Verbeuren TJ. New tripeptidic thrombin inhibitors; Influence of P2 and 3 residues on activity and selectivity. Bioorg Med Chem 1995; 3: 1019-24.
5. Callas D, Fareed J. Comparative pharmacology of site directed antithrombin agents. Implication in drug development. Thromb Haemost 1995; 74: 473-81.
6. Knabb RM, Luettgen JM, Laemy AW, Barbera FA, Kettner CA, Pangburn MJ and Thoolen MJ. Acute toxicity of synthetic thrombin inhibitors caused by inhibition of complement factor I. Circulation 1996, 94: I-696.
7. th American Chemical Society National Meeting, Division of Medicinal Chemistry" 1996; no127.
8. Rupin A, Mennecier P, De Nanteuil G, Laubie M, Verbeuren TJ. A screening procedure to evaluate the anticoagulant activity and the kinetic behaviour of direct thrombin inhibitors. Thromb Res 1995; 78: 217-25.
9. Isenman DE. Conformational changes accompanying proteolytic cleavage of human complement protein C3b by the regulatory enzyme factor I and its cofactor H. J Biol Chem 1983; 258: 4238-44.
10. Bieth J. Some kinetic consequences of the tight binding of protein-proteinase-inhibitors to proteolytic enzymes and their application to the determination of dissociation constants. In: Bayer-Symposium V: Proteinase inhibitors. H. Fritz et al. eds; Springer, Berlin, 1974; 463-9.
11. Stone SS, Tapparelli C. Thrombin inhibitors as antithrombotic agents: the importance of rapid inhibition. J Enzyme Inhibition 1995; 9: 3-15.
12. Stubbs MT, Bode W. A player of many parts: the spotlight falls on thrombin's structure. Thromb Res 1993; 69: 1-58.
13. Verbeuren TJ, Rupin A, Simonet S, Vallez MO, De Nanteuil G. Antithrombotic properties of S 18326. A new potent orally active tripeptidic boronic acid thrombin inhibitor. Thromb Haemost 1995; 73: 1310.
14. Lefkovits J., Topol E.J. Direct thrombin inhibitors in cardiovascular medicine. Circulation 1994; 90: 1522-36.
15. Verstraete M., Zoldhelyi P. Novel antithrombotic drugs in development. Drugs 1995; 49: 856-84.
16. Verbeuren TJ, Rupin A, Simonet S, Gloannec P, Lila C, Portevin B, De Nanteuil G. Pharmacological evaluation of two new tripeptidic boronic acid thrombin inhibitors, S17436 and S18326. In "Abstracts of the XIIIth International Symposium on Medicinal Chemistry" Sept. 19-23, 1994; Paris, pO1.